metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Allogeneic stem cell transplantation in the era of novel therapies for acute lym...
Journal Information
Vol. 153. Issue 1.
Pages 28-34 (July 2019)
Share
Share
Download PDF
More article options
Visits
5
Vol. 153. Issue 1.
Pages 28-34 (July 2019)
Review
Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia
El trasplante alogénico de progenitores hematopoyéticos en la era de las nuevas terapias en la leucemia linfoblástica aguda
Visits
5
Pere Barbaa,
Corresponding author
pbarba@vhio.net

Corresponding author.
, Izaskun Elorzab
a Servicio de Hematología, Hospital Universitario Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain
b Unidad de Trasplante de Progenitores Hematopoyéticos Pediátrica, Hospital Universitari Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Indications of allogeneic transplantation in adult acute lymphoblastic leukaemia depending on the clinical situation according to the European Society for Bone and Marrow Transplantation (EBMT).
Table 2. Indications for allogeneic transplantation in acute lymphoblastic leukaemia in high-risk adult (PETHEMA AR-2011 Protocol) and paediatric patients (LAL/SHOP-Pethema 2013 Protocol).
Show moreShow less
Abstract

Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.

Keywords:
Allogeneic transplantation
Acute lymphoblastic leukaemia
Immunotherapy
Monoclonal antibodies
CAR-T
Resumen

La inmunoterapia está cambiando profundamente el tratamiento de la leucemia linfoblástica aguda (LLA) infantil y del adulto. Sin embargo, a pesar de todos los avances, el trasplante alogénico de progenitores hematopoyéticos (alo-TPH) sigue siendo un pilar fundamental en su tratamiento. Cómo van a modificar estas nuevas terapias la indicación y el procedimiento de trasplante, resulta todavía incierto. En el presente artículo se discuten las indicaciones de TPH en la LLA infantil y del adulto, las posibles fuentes de donantes y acondicionamiento, así como el papel de la enfermedad residual medible en el contexto de la nueva era de tratamientos en el campo de la LLA.

Palabras clave:
Trasplante alogénico
Leucemia linfoblástica aguda
Inmunoterapia
Anticuerpos monoclonales
CAR-T

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2019.09.004
No mostrar más